FindTrial
Sign In

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer.

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220046
Enrollment
Unknown
Registered
2005-09-07
Start date
2005-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced (nonresectable/recurrent) gastric cancer

Interventions

investigational material(s) Generic name etc : TS-1 (tegafur + gimeracil + oteracil potassium), CDDP (cisplatin) INN of investigational material : TS-1:tegafur, gimeracil, oteracil potassium , CDDP:c

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with nonresectable or recurrent gastric cancer which is histologically confirmed adenocarcinoma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Survival and adverse events—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026